

From MedNess <newsletter@medness.org>

Para sarah@medness.org

Fecha miércoles, 16 de agosto de 2023 a las 17:47



MedNess (Onco-This-Week) *bite-size biopharma and medtech news*

August 16, 2023

Subscribe here

[Read this newsletter online](#)

MedNess News Highlights this week

FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate) for the Treatment of Patients with BRCA-Positive mCRPC

[Read the post](#)

Enrollment opens for Keytruda® Arm in Ongoing Breast Cancer alpha-lactalbumin and AMHR2-ED-targeting Vaccine Clinical Trial

[Read the post](#)

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

[Read the post](#)





Drug Approvals

FDA Approves TALVEY™ (talquetamab-tgvs) for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

"The clinically meaningful efficacy and safety profile observed with talquetamab in heavily pretreated patients in this clinical trial, which included patients treated with prior BCMA-targeted bispecific or CAR-T cell therapy, has been notable," said Ajai Chari, M.D., Director of Multiple Myeloma Program, Professor of Clinical Medicine at the University of California, San Francisco.* "Patients at this stage of disease have a poor prognosis. Talquetamab as a first-in-class therapy is a new option for patients with this difficult-to-treat blood cancer."

[Read more...](#)

FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate) for the Treatment of Patients with BRCA-Positive mCRPC

"As a physician, identifying patients with a worse prognosis is a priority, especially those whose cancers have a BRCA mutation," said Kim Chi, M.D., Medical Oncologist at BC Cancer – Vancouver and principal investigator of the Phase 3 MAGNITUDE study. "We prospectively designed the MAGNITUDE study to identify the subset of patients most likely to benefit from targeted treatment with AKEEGA and to help us understand how we can potentially achieve better health outcomes for patients."

[Read more...](#)

More news on
Drug Approvals

Regulatory news

No new posts! But check out more posts below

More news on
Regulatory News

Trial Results

No new posts! But check out more posts below

More news on
Trial Results

Trial Status

Enrollment opens for Keytruda® Arm in Ongoing Breast Cancer alpha-lactalbumin and AMHR2-ED-targeting Vaccine Clinical Trial

Dr. Amit Kumar, Chairman and CEO of Anixa stated, "Cleveland Clinic has demonstrated in both preclinical and clinical studies that our breast cancer vaccine induces an immune response—including, we believe, production of T cells that can target TNBC—so we believe that the addition of Keytruda could have a synergistic effect. If a vaccine induces the creation of T cells targeting TNBC, and Keytruda generally maintains T cell activity, the combination could be very potent. We are grateful to the U.S. Department of Defense for providing the funding for this new arm of the trial and look forward to Cleveland Clinic's presentation of the updated data from this trial at the San Antonio Breast Cancer Symposium (SABCS) in December."

[Read more...](#)

More news on
Trial Statuses

Business News

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

"By leveraging our extensive expertise, experience in cancer biology and unique technologies, we are focused on reinvigorating the immune system's ability to discover, disarm and destroy cancers in more patients. We are pursuing this ambitious goal through innovative and multifunctional modality platforms, using the capabilities at our global R&D sites as well as through partnership with external expert partners," said Adam Pearson, Chief Strategy Officer, Astellas. "We believe that this investment fits strategically with our long-term vision of expanding our capability in immuno-oncology and will ultimately lead to the development of new therapeutics for patients in need of cancer immunotherapy."

[Read more...](#)

Astex Expands Drug Discovery Collaboration With MSD

"Astex is applying its fragment-based drug discovery capability to design and generate small molecule modulators tailored to a wide range of potentially important therapeutic targets," said Harren Jhoti, president and CEO of Astex. "This new alliance builds on our existing productive collaboration and allows us to combine our expertise and assets with MSD's wide-ranging oncology capabilities."

[Read more...](#)

More Business
News

Editor's Desk



Richa Tewari, Managing Director and Contributing Author, Onco-This-Week



Shalini Roy Choudhury, Managing Editor



Anusha Jayaraman, Managing Editor



Siftjit Kaur, Social Media Manager



Himanshi Agarwal, Social Media Manager



Rueben Das, MedNess Neuro



Disclaimer

The editors take care to share authentic information. In case of any discrepancies please write to newsletter@medness.org

The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer to peer mentoring and support.

[Unsubscribe](#) | [Manage your subscription](#)